MedPath

A double-blind, randomized, double dummy, cross over, study to assess the difference in efficacy between nebulisation of rhDNase in the morning versus nebulisation before going to sleep.

Completed
Conditions
Cystic Fibrosis.
Registration Number
NL-OMON20146
Lead Sponsor
Roche Nederland BVPO Box 443440 AA WOERDENThe Netherlands
Brief Summary

Eur Respir J. 2007 Oct;30(4):763-8. Epub 2007 Jun 27.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
25
Inclusion Criteria

1. Proven CF, as evidenced by an abnormal sweat test or an abnormal rectum potential difference measurement or by the presence of two CF mutations and at least one clinical feature of CF.

2. Treated at the Erasmus MC - Sophia, and

Exclusion Criteria

Admission:

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pulmonary function test: MEF25.
Secondary Outcome Measures
NameTimeMethod
1. Pulmonary function tests: FVC, FEV1, Rint;<br /><br>2. Frequency and duration of coughing measured with audiorecording;<br /><br>3. Oxygenation at night recording transcutaneous oxygen saturation;<br /> percentage with saturation below 95%;<br /><br>4. Severity of cough with a VCD score;<br /><br>5. Sputum characteristics: amount, viscosity with a VAS-score;<br /><br>6. Quality of sleep and appetite with a VAS-score;<br /><br>7. Presence of morning sickness.
© Copyright 2025. All Rights Reserved by MedPath